Sr One Capital Management, Lp Top Holdings and 13F Report (2024) About Sr One Capital Management, LpInvestment ActivitySr One Capital Management, Lp has $319.40 million in total holdings as of March 31, 2024.Sr One Capital Management, Lp owns shares of 9 different stocks, but just 5 companies or ETFs make up 80% of its holdings.Approximately 10.62% of the portfolio was purchased this quarter.This quarter, Sr One Capital Management, Lp has purchased 6 new stocks and bought additional shares in 0 stocks.Sr One Capital Management, Lp sold shares of 0 stocks and completely divested from 0 stocks this quarter.Largest Holdings Arcellx $129,510,510CRISPR Therapeutics $56,653,844ARS Pharmaceuticals $34,149,805Alumis Inc. $26,066,617Mineralys Therapeutics $23,596,817 Largest New Holdings this Quarter Alumis Inc. $26,066,617 HoldingenGene Holdings Inc. $4,715,000 HoldingKALA BIO $3,145,556 Holding Largest Purchases this Quarter Alumis Inc. 1,959,896 shares (about $26.07M)enGene Holdings Inc. 500,000 shares (about $4.72M)KALA BIO 443,661 shares (about $3.15M) Sector Allocation Over TimeMap of 500 Largest Holdings ofSr One Capital Management, Lp Selling Neutral Buying Latest 13F Holdings and Changes Since Previous Quarterly FilingIssuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSectorACLXArcellx$129,510,5100.0%2,346,63040.5%MedicalCRSPCRISPR Therapeutics$56,653,8440.0%1,048,95117.7%MedicalSPRYARS Pharmaceuticals$34,149,8050.0%4,012,90310.7%MedicalAlumis Inc.$26,066,617$26,066,617 ▲New Holding1,959,8968.2%Common StockMLYSMineralys Therapeutics$23,596,8170.0%2,016,8227.4%MedicalDSGNDesign Therapeutics$21,863,6950.0%6,526,4766.8%MedicalNKTXNkarta$19,699,9980.0%3,333,3336.2%MedicalenGene Holdings Inc.$4,715,000$4,715,000 ▲New Holding500,0001.5%Common SharesKALAKALA BIO$3,145,556$3,145,556 ▲New Holding443,6611.0%MedicalShowing largest 100 holdings. View all holdings. More Institutional Buying and Selling Information SEC Filings and Trading Data SEC Filings 13F Filings Top 13F Buys Top 13F Sells Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.